Cluster Buying Strikes Again With AbbVie
A few weeks ago, I noticed a large insider buy at AbbVie (NYSE: ABBV), the giant pharmaceutical company that sells best-of-class drugs like Humira. It caught my eye, as the buy was for more than $1 million.
But that was not enough for me to issue a buy alert to War Room members.
One insider buy doesn’t represent anything unless it’s followed up by more buying from other insiders, especially officers of the company.
When only one insider buys shares, even if he or she makes multiple purchases, it’s not a good indication of anything more than faith in the company and a potential higher move on the horizon.
A single insider making multiple buys is more often than not a founder or major holder of the stock. Richard Kinder, co-founder and executive chairman of Kinder Morgan (NYSE: KMI), is an example of someone who makes these kinds of buys. Kinder often buys millions of dollars’ worth of shares in his own company. And the share price performance hasn’t really established any type of trend regardless of these purchases.
In the case of AbbVie, the insider buying has been sporadic… until now.
In the weeks following the first buy at AbbVie, several more insiders bought…
And they bought a lot! Since that first purchase in June, several insiders together bought more than $13 million worth of stock.
When several different insiders buy at varying prices over a short period of time, it’s called cluster buying… one of the best signals you can get about a stock and its direction.
As soon as I saw the latest insider buy, I formulated a trade recommendation to buy Long-Term Equity Anticipation Securities (LEAPS) on AbbVie.
My thinking was that we would jump in the trade, and if the shares moved higher in the short term, we would “leg in” to a spread to get our money off the table.
“Legging in” is a common strategy used to reduce the overall cost in a trade. This could take days, weeks or even months, which is why we use long-term options.
When you leg in to a spread, you sell options against the options that you own, similar to a covered call trade.
The play results in you taking some money off the table while limiting your upside to the spread (the dollar difference in the strike price between the calls you bought and the calls you sold).
AbbVie is a very strong company fundamentally. Because it is in the pharmaceutical sector, it has some volatility that can create quick profits… or losses. So we have to act fast to buy or engage a spread at the right time.
Action Plan: The War Room is the only place to beat the market to the punch in real time.
To learn more about the spread strategy and investing in high-quality situations like AbbVie’s, join us in The War Room today!
About Karim Rahemtulla
With more than 20 years of experience, Karim has mastered the subtle art of options trading. What we admire about him is his ability to score huge gains while minimizing the massive amount of risk that often comes with options. Beyond his expertise in options trading, he is also the author of the best-selling book Where in the World Should I Invest? He publishes weekly about smart speculation in his latest free e-letter, Trade of the Day.